GILD · News · 20260828N

Product / Drug Pipeline Progress

GILEAD SCIENCES, INC. · 2026-08-28 · Importance 38 · Surprise 60

Gilead Sciences received U.S. Food and Drug Administration approval for Bixlenvo on August 28, 2026. Bixlenvo is a once-daily HIV regimen intended for adults living with HIV infection. The regimen offers a smaller single-tablet option for patients currently using complex therapies, potentially supporting Gilead’s HIV product portfolio and future demand.

Key facts

• Bixlenvo is a once-daily HIV regimen that offers a smaller single-tablet option for patients on complex therapies. source